Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy

Basit Öğe Kaydı
dc.authorid0000-0003-2184-634X
dc.authorid0000-0002-0077-6971
dc.authorid0000-0002-0443-6966
dc.authorid0000-0001-7934-7039
dc.authorid0000-0003-2715-4002
dc.authorid0000-0002-5823-1704
dc.contributor.authorKutlu, Yasin
dc.contributor.authorGöktaş Aydın, Sabin
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÖven, Bala Başak
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorAçıkgöz, Özgür
dc.contributor.authorHamdard, Jamshid
dc.date.accessioned2023-04-28T09:20:32Z
dc.date.available2023-04-28T09:20:32Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractAtezolizumab is now the standard treatment for extensive-stage small cell lung cancer (ES-SCLC). Herein, we investigated the prognostic role of inflammatory markers in patients treated with atezolizumab plus chemotherapy and evaluated the efficacy and safety of adding atezolizumab to chemotherapy for patients with ES-SCLC and prognostic and predictive factors as a real-life experience. This retrospective study included 55 patients who received front-line atezolizumab with etoposide plus platin regimen for ES-SCLC. We analyzed the survival outcomes and factors that may predict response and survival. The objective response rate (ORR) was 81.8%. At a median follow-up of 23.5 months, the median progression-free survival (PFS) time was 10.8 months, and the median overall survival (OS) time was 15.2 months. In univariate analysis for PFS, limited-stage disease at the time of diagnosis, the presence of prophylactic cranial irradiation (PCI), the presence of liver metastasis, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) were found to be prognostic factors (P = .041, P = .034, P = .031, P = .004, and P = <.001, respectively). In other words, while the median PFS time was 14.1 months in patients with PLR ? 135.7, it was 7.5 months in patients with > 135.7. Similarly, median PFS was 14.9 months in patients with NLR ? 3.43, while it was 9.6 months in patients with > 3.43. Univariate analysis for OS revealed that limited stage at the time of diagnosis, NLR and PLR were significant prognostic indicators (P = .01, P = .006, and P = .007, respectively). Median OS time for patients with both NLR ? 3.43 and PLR ? 135.7 was significantly better than that of patients with NLR > 3.43 and PLR > 135.7 (16.9 vs 11.3 and 16.9 vs 11.5 months, respectively). Logistic regression analysis demonstrated that PLR was an independent significant predictive factor for the response to atezolizumab plus chemotherapy (OR: 0.07, P = .028). The patients with PLR ? 135.7 were significantly good responders to atezolizumab plus chemotherapy treatment. Real-life data demonstrated a significant correlation between survival and NLR and, PLR in ES-SCLC patients treated with atezolizumab. In addition, PLR was a significant predictive indicator of response to atezolizumab plus chemotherapy.
dc.identifier.citationKutlu, Y., Göktaş Aydın, S., Bilici, A., Öven, B. B., Ölmez, Ö. F., Açıkgöz, Ö. ... Hamdard, J. (2023). Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine, 102(15), e33432-e33432. https://dx.doi.org/10.1097/MD.0000000000033432
dc.identifier.doi10.1097/MD.0000000000033432
dc.identifier.endpagee33432
dc.identifier.issn1536-5964
dc.identifier.issn0025-7974
dc.identifier.issue15
dc.identifier.pmid37058061
dc.identifier.scopus2-s2.0-85152624198
dc.identifier.scopusqualityN/A
dc.identifier.startpagee33432
dc.identifier.urihttps://dx.doi.org/10.1097/MD.0000000000033432
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10904
dc.identifier.volume102
dc.identifier.wos000971756700041en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorKutlu, Yasin
dc.institutionauthorGöktaş Aydın, Sabin
dc.institutionauthorBilici, Ahmet
dc.institutionauthorÖlmez, Ömer Fatih
dc.institutionauthorAçıkgöz, Özgür
dc.institutionauthorHamdard, Jamshid
dc.language.isoen
dc.publisherNLM (Medline)
dc.relation.ispartofMedicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAtezolizumab
dc.subjectNeutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio
dc.subjectSmall Cell Lung Cancer
dc.titleNeutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Kutlu-Yasin-2023.pdf
Boyut:
724.47 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu